Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Race Oncology is pleased to release an investor webinar video, where Race’s Executive Chair Dr Peter Smith and CEO and Managing Directot Dr Daniel Tillett presented latest updates of the company’s Phase 1 clinical trial, followed by an investor Q&A. 

✅ Ethics Approval Secured – The RC220 bisantrene Phase 1 clinical trial has received approval from Bellberry HREC, marking a significant step in advancing Race’s novel formulation to human clinic.
✅ Focus on Cancer Survivorship – The trial will explore RC220’s cardioprotective capability as well as its anti-cancer efficacy.
✅ Trial Overview – A two-part Phase 1 study that assesses RC220’s safety, tolerability and pharmacokinetics, with patient recruitment across Australia, Hong Kong, and South Korea.
✅ Expected News Flow in 2025 – As an open-label trial, results will be reported progressively, generating continuous news flow throughout the year.

Race Oncology Investor Briefing Session March 17th, 2025